MedTrace Logo

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1755

Last updated 2022-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.

Conditions

Interventions

DRUG

Bamlanivimab

Administered IV.

DRUG

Etesevimab

Administered IV.

DRUG

Placebo

Administered IV.

DRUG

VIR-7831

Administered IV.

DRUG

Bebtelovimab

Administered IV.

Sponsors & Collaborators

  • AbCellera Biologics Inc.

    collaborator INDUSTRY

  • Shanghai Junshi Bioscience Co., Ltd.

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Vir Biotechnology, Inc.

    collaborator INDUSTRY

  • Eli Lilly and Company

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2021-07-27
Completion
2021-10-18
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04634409 on ClinicalTrials.gov